Last reviewed · How we verify
Halflytely (BISACODYL)
At a glance
| Generic name | BISACODYL |
|---|---|
| Sponsor | Braintree |
| Drug class | Stimulant Laxative [EPC] |
| Target | Kappa-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
- Constipation
- Incomplete passage of stool
Common side effects
Key clinical trials
- RELISTOR's Effects on Opioid-Induced Constipation
- Optimization of Postoperative Bowel Habits (NA)
- Effects of a 5-Week Probiotic Supplementation Intervention on Markers of Delayed Onset Muscle Soreness (NA)
- Bisacodyl Oral for Lowering Dysfunction (of Tenckhoff Catheter) (PHASE4)
- Alii Supplement Study (PHASE2)
- 4-L Split-dose Polyethylene Glycol and Bisacodyl and Docusate Sodium Regimen Versus 2-L Split-dose Polyethylene Glycol Plus Oral Simethicone Regimen for Bowel Preparation Before Colonoscopy (NA)
- Effects of Constipation Treatment in Chronic Kidney Disease: A Pilot Feasibility Trial (NA)
- The Effect of Video-Based Education on Colonoscopy Preparation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Halflytely CI brief — competitive landscape report
- Halflytely updates RSS · CI watch RSS
- Braintree portfolio CI